Pharmaceutical Company Explodes Higher After Study Shows Positive Data For Cystic Fibrosis Drug
In pre-market trading, shares were up as much as 55%.
Vertex's study showed, "statistically significant improvement" in lung function for cystic fibrosis patients with a certain gene mutation.
Adam Feuerstein of TheStreet wrote following the results that they were, "Maybe not a home run, per se, but sticking with the baseball analogy, I'd say the study results are a base-clearing triple."
Vertex said that it will seek approval for the treatment with the U.S. FDA and European Medicines Agency in the fourth quarter.
Feuerstein wrote in his report that last year, he laid out a way Vertex could generate $10 billion annual sales from cystic fibrosis treatments. These results are a huge part of that equation.
These results are a great example of the binary events that pharmaceutical investors face when a company's drug trial results or regulatory approvals are released.
Following a trial result or regulatory meeting, shares of pharmaceutical companies are apt to rally sharply higher or completely tank.
Today, Vertex shareholders will feel like winners.
- 6 reasons why you should visit Ladakh this summer
- TVS iQube gets a new variant priced under ₹1 lakh, ST variant gets a bigger battery
- As English players begin their premature IPL exodus, Gavaskar calls for action against England Cricket Board
- Top 10 destinations for river rafting in India in 2024
- Should you enrol your child in an online university like IGNOU?